Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Study of Naxitamab, Gemcitabine and TGFβi NK Cells in Advanced Breast Cancers
NCT06026657Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Lymphokine-Activated Killer Cells, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of transforming growth factor-beta-imprinted natural killer cells, naxitamab in breast cancer. Started Apr 2024; status: recruiting.
02
Drugs
transforming growth factor-beta-imprinted natural killer cellsnaxitamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06026657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026657.